AbCellera Biologics
ABCL
201 hedge funds and large institutions have $1.3B invested in AbCellera Biologics in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 78 increasing their positions, 58 reducing their positions, and 21 closing their positions.
145% more call options, than puts
Call options by funds: $19M | Put options by funds: $7.75M
67% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 21
34% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 58
7% more capital invested
Capital invested by funds: $1.21B → $1.3B (+$86.5M)
6% more funds holding
Funds holding: 190 → 201 (+11)
1.96% more ownership
Funds ownership: 42.73% → 44.69% (+2%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$73.2M |
| 2 |
BlackRock
New York
|
+$14.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11.2M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$8.24M |
| 5 |
CC
Casdin Capital
New York
|
+$7.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCAC
Guardian Capital Advisors (Canada)
Toronto,
Ontario, Canada
|
-$22.5M |
| 2 |
Renaissance Technologies
New York
|
-$9.92M |
| 3 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
-$5.8M |
| 4 |
Millennium Management
New York
|
-$5.1M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$4.8M |
ABCL Hedge Fund Activity: Q4 2022 in Review
201 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q4 2022, worth a combined $1.3B — up 7.2% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ABCL positions and 21 closed out — a net gain of 14 holders — while 78 added to existing stakes and 58 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $73.2M. The largest seller was Guardian Capital Advisors (Canada), cutting an estimated $22.5M.
- 201 institutional investors held AbCellera Biologics (ABCL) as of Q4 2022, up from 190 in Q3 2022.
- Funds reported $1.3B of AbCellera Biologics stock for Q4 2022, up 7.2% quarter-over-quarter.
- 35 funds opened new AbCellera Biologics positions in Q4 2022 and 21 closed out, a net change of +14 holders.
- The largest AbCellera Biologics buyer in Q4 2022 was Baillie Gifford & Co, an estimated $73.2M added.
- The largest AbCellera Biologics seller in Q4 2022 was Guardian Capital Advisors (Canada), an estimated $22.5M sold.
Based on aggregated 13F filings for Q4 2022.